Previous 10 | Next 10 |
Kahn Brothers’ 13F portfolio value increased from $528M to $579M this quarter. New York Community Bancorp, VOXX International, BlackBerry, and Patterson-UTI Energy were decreased during the quarter. The portfolio continues to be very concentrated with the top five positions...
My passive income was down during y/y January, due to the Disney dividend cut. However, on an adjusted basis, it was up 14.3%. I underperformed the market slightly in January, though strong earnings reports across my portfolio give me solace moving forward. I made two non-sche...
If you've ever breathed a sigh of relief at the pharmacy register because your generic medication was cheaper than the brand-name version, you've experienced the economic power of pharmaceutical manufacturers. By undercutting the branded competition, big manufacturers save you money -- whil...
Viatris Inc. to Hold Conference Call on Monday, Feb. 22, 2021, to Discuss 2021 Financial Guidance Viatris to host its inaugural virtual Investor Day on March 1, 2021, as previously announced PR Newswire PITTSBURGH , Feb. 9, 2021 /PRNewswire/ -- Viatris I...
We share the remaining top pick ideas from our Marketplace contributors. There are a wide variety - including biotech, precious metals, dividend, and energy ideas. Later on this week we will share the public Google Sheet that will track the performance of these ideas in real-time....
You probably wouldn't have a hard time coming up with the names of ridiculously overvalued stocks on the market right now. Just type "short squeeze" into a search engine and look at the most recent news headlines if you can't think of any. Naming stocks that are bargains will likely be ...
In early December, Court of Appeals heard oral argument regarding Biogen's only unexpired patent on Tecfidera, which was found invalid by a West Virginia judge. Biogen's CEO said at the JP Morgan Conference a couple weeks ago that the company will face abrupt erosion of Tecfidera in 2...
The FTC today issued a final order with conditions on Pfizer's (PFE) spinoff of its Upjohn business and combination with Mylan, doing business as Viatris (VTRS).Citing harm to competition in 10 generic drug markets - seven in the U.S. by reducing the number of suppliers, and three where the m...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Markets love resolution and COVID-19 vaccine successes en...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Markets love resolution and COVID-19 vaccine successes en...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...